Two proprietary IDO inhibitor drugs with distinct pharmacological characteristics,10 1MT and navoximod (NLG-919), had little or no antitumor effects as monotherapies, and did not improve outcomes following CDA treatment. The gene discussed is IDO1; the disease is congenital dyserythropoietic anemia.